These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 30556769

  • 1. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients.
    Gülez N, Makay B, Sözeri B.
    Mod Rheumatol; 2020 Jan; 30(1):166-171. PubMed ID: 30556769
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y, Gezer HH, Duruöz MT.
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [Abstract] [Full Text] [Related]

  • 5. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T, Aydın F, Nilüfer Tekgöz P, Sezer M, Uncu N, Çelikel Acar B.
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
    Kisla Ekinci RM, Balci S, Dogruel D, Altintas DU, Yilmaz M.
    Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
    [Abstract] [Full Text] [Related]

  • 9. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y.
    Adv Rheumatol; 2020 Jan 30; 60(1):12. PubMed ID: 32000860
    [Abstract] [Full Text] [Related]

  • 10. An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.
    Shehadeh K, Levinsky Y, Kagan S, Zuabi T, Tal R, Aviran NH, Butbul Aviel Y, Tirosh I, Spielman S, Miller-Barmak A, Semo Oz R, Harel L, Chodick G, Amarilyo G.
    Int Immunopharmacol; 2024 May 10; 132():111967. PubMed ID: 38569431
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S.
    Front Immunol; 2020 May 10; 11():971. PubMed ID: 32670263
    [Abstract] [Full Text] [Related]

  • 13. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
    Sendogan DO, Saritas H, Kumru G, Eyupoglu S, Sadioglu RE, Tuzuner A, Sengul S, Keven K.
    Transplant Proc; 2019 Sep 10; 51(7):2292-2294. PubMed ID: 31400972
    [Abstract] [Full Text] [Related]

  • 14. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
    Çakan M, Karadağ ŞG, Ayaz NA.
    Turk J Pediatr; 2020 Sep 10; 62(2):167-174. PubMed ID: 32419407
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
    Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H, Karadeniz H, Guler AA, Salman RB, Goker B, Ozturk MA, Haznedaroglu S, Tufan A.
    Clin Exp Rheumatol; 2021 Sep 10; 39 Suppl 132(5):30-36. PubMed ID: 34251317
    [Abstract] [Full Text] [Related]

  • 16. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
    N Engl J Med; 2018 May 17; 378(20):1908-1919. PubMed ID: 29768139
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A.
    Mod Rheumatol; 2019 Mar 17; 29(2):363-366. PubMed ID: 29578360
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
    Matsumoto H, Ohashi H, Fujita Y, Yoshida S, Yokose K, Temmoku J, Matsuoka N, Shinden Y, Kusano K, Sonobe T, Nakamoto Y, Yashiro-Furuya M, Asano T, Sato S, Suzuki E, Yago T, Watanabe H, Migita K.
    Tohoku J Exp Med; 2022 Feb 17; 256(2):169-174. PubMed ID: 35236806
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.